Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Greg was also central to the planning, design, and construction of this facility
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Further strengthens BaseLaunch's global pharma industry partnerships
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Subscribe To Our Newsletter & Stay Updated
